RxDoctor Payments Data

M Sharif, MD

Cardiovascular Disease · Lubbock, TXNPI 1013910546

Payments from drug & device makers

$75,095in general payments, 2019–2025

Across 900 payments — averaging $83.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$29K
  • Abbott$16K
  • Johnson & Johnson$11K
  • Penumbra, Inc.$10K
  • Boston Scientific$2K
  • Cvrx, Inc.$2K
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$9,90013%
  • Travel & lodging$41,11455%
  • Food & beverage$23,80332%
  • Education$2770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,095 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$531,909
Medicare patients
1,786
Services billed
6,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,479$1,381,484
XareltoRivaroxaban318$328,480
EntrestoSacubitril/Valsartan243$231,397
MultaqDronedarone Hcl163$197,472
Repatha SureclickEvolocumab237$157,044
CamzyosMavacamten12$91,609
JardianceEmpagliflozin74$66,831
BrilintaTicagrelor108$63,651
FarxigaDapagliflozin Propanediol56$61,918
VascepaIcosapent Ethyl97$48,439
Metoprolol Succinate2,368$36,071
Icosapent Ethyl74$18,207
Atorvastatin Calcium2,314$16,932
Rosuvastatin Calcium1,354$13,932
Amiodarone Hcl754$13,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$236$1,381,4841,479 claims
Johnson & JohnsonXarelto$11,308$328,480318 claims
NovartisEntresto$347$231,397243 claims
Sanofi-aventis U.S. LLCMultaq$136$197,472163 claims
AstraZenecaBrilinta, Farxiga$365$125,569164 claims
E.r. Squibb & Sons, L.L.C.Camzyos$190$91,60912 claims
Boehringer IngelheimJardiance$86$66,83174 claims
Kowa Pharmaceuticals America, Inc.Livalo$12$6,34915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →